Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stelara Induction Optimization in Crohn's Disease
NCT04629196Phase 4Terminated
- Sponsor
- NYU Langone Health
- Start
- Feb 2022
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ustekinumab in Crohn's disease, sponsored by NYU Langone Health. Started Feb 2022; status: terminated.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04629196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04629196.